Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. Jean-Francois Geschwind

Jean-Francois Henri Geschwind, MD

Chief, Divison of Interventional Radiology
Professor of Radiology and Radiological Science
Male
Appointment Phone

410-614-2227

Main Location

The Johns Hopkins Hospital

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Chief, Divison of Interventional Radiology
  • Director, Cardiovascular Diagnostic Laboratory
  • Professor of Radiology and Radiological Science
  • Professor of Oncology

Centers & Institutes

  • Interventional Radiology Center
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Expertise

Biliary Disease, Chronic Total Occlusions, Claudication, Interventional Radiology, Liver Disease, Lower Extremity Angioplasty, Lower Extremity Stenting, Neuroendocrine Tumors, Peripheral Arterial Disease, Peripheral Vascular Disease, Renal Artery Disease, Renal Vascular Disease, Varicocele, Vascular and Interventional Radiology, Vascular Malformations, Venous Thromboembolism, Visceral Angioplasty, Visceral Stenting

Research Interests

Liver cancer

Biography

Dr. Jean-Francois (Jeff) Geschwind is a Professor in the Johns Hopkins Medicine Department of Radiology and Department of Oncology. He serves as Director of the Division of Vascular and Interventional Radiology at the Johns Hopkins University School of Medicine and the Director of the Interventional Radiology Center at The Johns Hopkins Hospital.

Dr. Geschwind’s clinical expertise focuses on treating hepatic cancer and other malignancies. He is considered a key opinion leader in the field of liver cancer.

A native of France, Dr. Geschwind received his medical degree from Boston University School of Medicine in 1991. He performed his residency training as a research scholar (sponsored by the NIH) in diagnostic radiology at the University of California at San Francisco (UCSF) in 1996, where his research focused on cardiac magnetic resonance imaging. Dr. Geschwind completed his training in vascular and interventional radiology at Johns Hopkins and joined the faculty in 1998 as an Assistant Professor.

He has authored or co-authored more than 350 published scientific articles and abstracts on interventional oncology and specifically the treatment of liver cancer. Dr. Geschwind also co-authored the first book dedicated to interventional oncology, titled Interventional Oncology Principles and Practice.

Dr. Geschwind has won numerous national and international awards, including the Merit Award from the American Society of Clinical Oncology for pioneering work in the field of drug delivery for liver cancer. He serves as the Consultant to the Editor of the journal Radiology, which has long been recognized as the premier radiology journal, and is on several editorial boards. He is also a founding member of the International Liver Cancer Association and is an active member of many other associations including the American Society of Clinical Oncology.

Languages

  • English
  • French

Memberships

Eastern Cooperative Oncology Group

American Society of Clinical Oncology

American Roentgen Ray Society

American Association for Cancer Research

Association of University Radiologists

Cardiovascular and Interventional Society of Europe

Society of Interventional Radiology

Radiology Society of North America

Association of California Interns and Residents

California Medical Association

Chesapeake Interventional Radiology Society

Clinical Trial Keywords

  • Interventional oncology

Additional Resources

Additional Resources +
  • Education +

    Training

    • Boston University School of Medicine (Boston MA) (1991)

    Residencies

    • University of California San Francisco / Radiology (San Francisco CA) (1996)

    Certifications

    • American Board of Radiology / Diagnostic Radiology (1998)
  • Research & Publications +

    Research Summary

    Dr. Geschwind's primary research interests include finding new therapies for liver cancer, assessing tumor response after therapy using functional MR imaging and investigating new drug delivery systems for locoregional cancer therapy. Along with colleagues from the Departments of Radiology and Medicine, he has focused his research further into developing a new therapeutic approach for liver cancer using drugs specifically designed to block tumor metabolism in cancer cells.

    Selected Publications

    1. Liapi, E.; JF, H.G.; Vali, M.; Khwaja, A.A.; Prieto-Ventura, V.; Buijs, M.; Vossen, J.A.; Ganapathy, S.; Wahl, R.L. Assessment of Tumoricidal Efficacy and Response to Treatment with 18F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor. J Nucl Med. 2011 Feb;52(2):225-230.
    2. Liapi, E.; Geschwind, J.F. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol. 2011 Feb;34(1):37-49.
    3. Golzarian, J.; Sapoval, M.; Kundu, S.; Hunter, D.; Brountzo, E.; Geschwind, J.; Murphy, T.; Spies, J.; Wallace, M.; de Baere, T.; Cardella, J. Guidelines for Peripheral and Visceral Vascular Embolization Training: joint writing groups of the Standards of Practice Committees for the Society of Interventional Radiology (SIR), Cardiovascular and Interventional Radiological Society of Europe (CIRSE), and Canadian Interventional Radiology Association (CIRA). J Vasc Interv Radiol 2010 2010 Apr;21(4):436-441.
    4. Schwarz, R.E.; Abou-Alfa, G.K.; Geschwind, J.F.; Krishnan, S.; Salem, R.; Venook, A.P. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford). 2010 Jun;12(5):313-320.
    5. Loffroy, R.; Rao, P.; Ota, S.; Geschwind, J.F. Renal artery embolisation prior to radical nephrectomy for renal cell carcinoma: when, how and why? Br J Radiol. 2010 Jul;83(991):630; author reply 631-632.
    6. Loffroy, R.; Rao, P.; Ota, S.; De Lin, M.; Kwak, B.K.; Krause, D.; Geschwind, J.F. Packing technique for endovascular coil embolisation of peripheral arterial pseudo-aneurysms with preservation of the parent artery: safety, efficacy and outcomes. Eur J Vasc Endovasc Surg. 2010 Aug;40(2):209-215.
    7. Loffroy, R.; Rao, P.; Ota, S.; De Lin, M.; Kwak, B.K.; Geschwind, J.F. Embolization of acute nonvariceal upper gastrointestinal hemorrhage resistant to endoscopic treatment: results and predictors of recurrent bleeding. Cardiovasc Intervent Radiol. 2010 Dec;33(6):1088-1100.
    8. Loffroy, R.; Rao, P.; Kwak, B.K.; Ota, S.; De Lin, M.; Liapi, E.; Geschwind, J.F. Transcatheter arterial embolization in patients with kidney diseases: an overview of the technical aspects and clinical indications. Korean J Radiol. 2010 May-Jun;11(3):257-268.
    9. Lin, M.; Loffroy, R.; Noordhoek, N.; Taguchi, K.; Radaelli, A.; Blijd, J.; Balguid, A.; Geschwind, J.F. Evaluating tumors in transcatheter arterial chemoembolization (TACE) using dual-phase cone-beam CT. Minim Invasive Ther Allied Technol. 2010 Nov 17;Epub Nov. 17.
    10. Loffroy, R.; Gergele, F.; Rao, P.; Geschwind, J.F. Endovascular management of a posttraumatic pseudoaneurysm of the common carotid artery with superselective coil embolization. J Vasc Surg. 2010 May 25;Epub May, 2010.
    11. Liapi, E.; Geschwind, J.F. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010 May;17(5):1234-1246.
    12. Liapi, E.; Geschwind, J.F. Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer. J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):405-406.
    13. Liapi, E.; Geschwind, J.F. Chemoembolization for primary and metastatic liver cancer. Cancer J. 2010 2010 Mar-Apr;16(2):156-162.
    14. Liapi, E.; Geschwind, J. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol 2010;17(5):1234-1246.
    15. Liapi, E.; Geschwind, J. Chemoembolization for primary and metastatic liver cancer. Cancer J. 2010 2010 Mar-Apr;16(2):156-162.
    16. Lee, K.H.; Liapi, E.A.; Cornell, C.; Reb, P.; Buijs, M.; Vossen, J.A.; Ventura, V.P.; Geschwind, J.F. Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Intervent Radiol. 2010 Jun;33(3):576-582.
    17. Hong, K.; Geschwind, J.F. Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. Semin Oncol. 2010 Apr;37(2):110-117.
    18. Ganapathy-Kanniappan, S.; Vali, M.; Kunjithapatham, R.; Buijs, M.; Syed, L.H.; Rao, P.P.; Ota, S.; Kwak, B.K.; Loffroy, R.; Geschwind, J.F. 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr Pharm Biotechnol. 2010 Aug;11(5):510-517.
    19. Ganapathy-Kanniappan, S.; Geschwind, J.F.; Kunjithapatham, R.; Buijs, M.; Syed, L.H.; Rao, P.P.; Ota, S.; Vali, M. The Pyruvic Acid Analog 3-Bromopyruvate Interferes with the Tetrazolium Reagent MTS in the Evaluation of Cytotoxicity. Assay Drug Dev Technol. 2010 Apr;8(2):258-262.
    20. Ganapathy-Kanniappan, S.; Geschwind, J.F.; Kunjithapatham, R.; Buijs, M.; Syed, L.H.; Rao, P.P.; Ota, S.; Kwak, B.K.; Loffroy, R.; Vali, M. 3-Bromopyruvate Induces Endoplasmic Reticulum Stress, overcomes Autophagy and causes Apoptosis in Human HCC Cell Lines. Anticancer Res. 2010 Mar;30(3):923-935.
    21. Ganapathy-Kanniappan, S.; Geschwind, J.; Kunjithapatham, R.; Buijs, M.; Syed, L.; Rao PP; Ota, S.; Vali, M. The pyruvic acid analog 3-bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity. . Assay Drug Dev Technol 2010 2010 Apr;8(2):258-262.
    22. Frangakis, C.; Geschwind, J.F.; Kim, D.; Chen, Y.; Koteish, A.; Hong, K.; Liapi, E.; Georgiades, C.S. Chemoembolization Decreases Drop-Off Risk of Hepatocellular Carcinoma Patients on the Liver Transplant List. Cardiovasc Intervent Radiol. 2010 Dec 30.
    23. De Jong, M.C.; Farnell, M.B.; Sclabas, G.; Cunningham, S.C.; Cameron, J.L.; Geschwind, J.F.; Wolfgang, C.L.; Herman, J.M.; Edil, B.H.; Choti, M.A.; Schulick, R.D.; Nagorney, D.M.; Pawlik, T.M. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg. 2010 Jul;252(1):142-148.
    24. Reyes, D.K.; Vossen, J.A.; Kamel, I.R.; Azad, N.S.; Wahlin, T.A.; Torbenson, M.S.; Choti, M.A.; Geschwind, J.F. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009 Nov-Dec;15(6):526-532.
    25. Reyes, D.K.; Vossen, J.A.; Kamel, I.R.; Azad, N.S.; Wahlin, T.A.; Torbenson, M.S.; Choti, M.A.; Geschwind, J.F. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009 Nov-Dec;15(6):526-532.
    26. Kamel, I.R.; Liapi, E.; Reyes, D.K.; Zahurak, M.; Bluemke, D.A.; Geschwind, J.F. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009 Feb;250(2):466-473.
    27. Hong, K.; McBride, J.D.; Georgiades, C.S.; Reyes, D.K.; Herman, J.M.; Kamel, I.R.; Geschwind, J.F. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol. 2009 Mar;20(3):360-367.
    28. Buijs, M.; Vossen, J.A.; Geschwind, J.F.; Ishimori, T.; Engles, J.M.; Acha-Ngwodo, O.; Wahl, R.L.; Vali, M. Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drugs. 2009 Apr;27(2):120-123.
    29. Vossen, J.A.; Kamel, I.R.; Buijs, M.; Liapi, E.; Georgiades, C.S.; Hong, K.; Geschwind, J.F. Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization. J Comput Assist Tomogr. 2008 May-Jun;32(3):347-352.
      Yung, R.C. Epidemiology, diagnosis, staging, medical and surgical management of Lung Cancer. In: Geschwind, J.F.; Soulen, M.C., editors, Interventional Oncology: Principles and Practice; 2008.
    30. Vossen, J.A.; Buijs, M.; Syed, L.; Kutiyanwala, F.; Kutiyanwala, M.; Geschwind, J.F.; Vali, M. Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization. Clin Exp Metastasis. 2008;25(7):811-817.
    31. Liapi, E.; Geschwind, J.F.; Vossen, J.A.; Buijs, M.; Georgiades, C.S.; Bluemke, D.A.; Kamel, I.R. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol. 2008 Jan;190(1):67-73.
    32. Lee, K.H.; Liapi, E.; Vossen, J.A.; Buijs, M.; Ventura, V.P.; Georgiades, C.; Hong, K.; Kamel, I.; Torbenson, M.S.; Geschwind, J.F. Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol. 2008 Oct;19(10):1490-1496.
    33. Buijs, M.; Vossen, J.A.; Hong, K.; Georgiades, C.S.; Geschwind, J.F.; Kamel, I.R. Chemoembolization of hepatic metastases from ocular melanoma: assessment of response with contrast-enhanced and diffusion-weighted MRI. AJR Am J Roentgenol. 2008 Jul;191(1):285-289.
      El-Khouli, R.H.; Geschwind, J.F.; Bluemke, D.A.; Kamel, I.R. Solitary fibrous tumor of the liver: magnetic resonance imaging evaluation and treatment with transarterial chemoembolization. J Comput Assist Tomogr. 2008 Sep-Oct;32(5):769-771.
    34. Buijs, M.; Vossen, J.A.; Frangakis, C.; Hong, K.; Georgiades, C.S.; Chen, Y.; Liapi, E.; Geschwind, J.F. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization-single-center experience. Radiology. 2008 Oct;249(1):346-354.
    35. Kamel, I.R.; Reyes, D.K.; Liapi, E.; Bluemke, D.A.; Geschwind, J.F. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2007 Jan;18(1 Pt 1):49-56.
    36. Dorfman, J.D.; Schulick, R.; Choti, M.A.; Geschwind, J.F.; Kamel, I.; Torbenson, M.; Thuluvath, P.J. Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States. World J Gastroenterol. 2007 Feb 7;13(5):781-784.
    37. Buijs, M.; Kamel, I.R.; Vossen, J.A.; Georgiades, C.S.; Hong, K.; Geschwind, J.F. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol. 2007 Aug;18(8):957-963.
    38. Kamel, I.R.; Bluemke, D.A.; Eng, J.; Liapi, E.; Messersmith, W.; Reyes, D.K.; Geschwind, J.F. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006 Mar;17(3):505-512.
    39. Ganapathy-Kanniappan S, Vali M, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, and Geschwind JF. 3-Bromopyruvate: A New Targeted Antiglycolytic Agent and a Promise for Cancer Therapy. Curr Pharm Biotechnol. 2010 Apr 26.
    40. Liapi E, and Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010 May;17(5):1234-46. Epub 2010 Apr 20.
    41. Loffroy R, Rao P, Ota S, De Lin M, Kwak BK, Krause D, and Geschwind JF. Packing Technique for Endovascular Coil Embolisation of Peripheral Arterial Pseudo-aneurysms with Preservation of the Parent Artery: Safety, Efficacy and Outcomes. Eur J Vasc Endovasc Surg. 2010 Apr 14.
    42. Liapi E. and Geschwind JF. Chemoembolization for Primary and Metastatic Liver Cancer. Cancer J 2010; 16:156-162.
    43. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, Vali M. 3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines. Anticancer Res. 2010 Mar;30(3):923-35.
    44. Golzarian J, Sapoval MR, Kundu S, Hunter DW, Brountzos EN, Geschwind JF, Murphy TP, Spies JB, Wallace MJ, de Baere T, Cardella JF. Guidelines for Peripheral and Visceral Vascular Embolization Training: joing writing groups of the Standards of Practice Committees for the Society of Interventional Radiology (SIR), Cardiovascular and interventional Radiological Society of Europe (CIRSE), and Canadian Interventional Radiology Association (CIRA). J Vasc Interv Radiol. 2010 Apr; 21(4):436-41.
    45. Loffroy R, Rao P, Ota S, De Lin M, Kwak BK, Geschwind JF. Embolization of Acute Nonvariceal Upper Gastrointestinal Hemorrhage Resistant to Endoscopic Treatment: Results and Predictors of Recurrent Bleeding. Cardiovasc Intervent Radiol. 2010 Mar 16.
    46. Lee KH, Liapi, EA, Cornell C, Reb P, Buijs M, Vossen JA, Ventura VP, Geschwind JF. Doxorubicin-Loaded QuadraSphere Microspheres: Plasma Pharmacokinetics and Intratumoral Drug Concentration in an Animal Model of Liver Cancer. Cardiovasc Intervent Radio. 2010 Jan 20.
    47. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Vali M. The Pyruvic Acid Analog 3-Bromopyruvate Interferes With the Tetrazolium Reagent MTS in the Evaluation of Cytotoxicity. Assay Drug Dev Technol 2010 Jan.
    48. Reyes DK, Vossen JA, Kamel IR, Azad N, Wahlin T, Torbenson M, Choti MA, and Geschwind JF. Single Centre Phase II Trial of Transarterial Chemoembolization with Drug Eluting Beads for Patients with Unresectable Hepatocellular Carcinoma: Initial Experience in the USA. Cancer Journal 2009 ; 15:526-532.
    49. Ganapathy-Kanniappan S, Geschwind J.F., Kunjithapatham R, Buijs M, Vossen J, Tchernyshyov I, Cole R, Syed L, Rao P, Ota S, Vali M. Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) is Pyruvylated during 3-Bromopyruvate Mediated Cancer Cell Death. Anticancer Res. 2009 Dec;29(12):4909-4918.
    50. Liapi E, and Geschwind J.F. Interventional oncology: new options for interstitial treatments and intravascular approaches. Targeting tumor metabolism via a loco-regional approach: A new therapy against liver cancer. J Hepatobiliary Pancreat Surg. 2009
    51. Jain A, Smith C, Geschwind JF, and Pawlik TM. Image of the month: Gastrohepatic fistula following TACE for hepatocellular carcinoma. Arch Surg. 2009 Mar;144(3):285-6.
    52. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, and Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009 Feb;250(2):466-73.
    53. Taguchi K, Funama Y, Zhang M, Fishman EK, and Geschwind JF. Quantitative measurement of iodine concentration in the liver using abdominal C-arm computed tomography. Acad Radiol. 2009 Feb;16(2):200-8.
    54. Lee KH, Liapi E, Buijs M, Vossen J, Hong K, Georgiades C, and Geschwind JF. Considerations for implantation site of Vx-2 carcinoma into rabbit liver. J Vasc Interv Radiol. 2009 Jan;20(1):113-7.
    55. El-Khouli RH, Geschwind JF, Bluemke DA, and Kamel IR. Solitary fibrous tumor of the liver: magnetic resonance imaging evaluation and treatment with transarterial chemoembolization. J Comput Assist Tomogr. 2008 Sep-Oct;32(5):769-71.
    56. Buijs M, Vossen, JA, Frangakis C, Hong K, Georgiades CS, Chen Y, Liapi E, and Geschwind JF. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization-single-center experience. Radiology 2008 Oct; 249(1):346-54.
    57. Assumpcao L, Cameron JL, Wolfgang CL, Edil B, Choti MA, Herman JM, Geschwind JF, Hong K, Georgiades C, Schulick RD, Pawlik TM. Incidence and Management of Chyle Leaks Following Pancreatic Resection: A High Volume Single-Center Institutional Experience. J Gastrointest Surg. 2008 Aug 7.

    Clinical Trials

    Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

    Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

    Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH)

    Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer

  • Academic Affiliations & Courses +
  • Activities & Honors +

    Honors

    Outstanding Faculty Award, Society of Interventional Radiology 35th Annual Scientific Meeting, Tampa, Florida, 2010

    Journal of Vascular and Interventional Radiology, Distinguished Reviewer Award, 2009

    Journal of Vascular and Interventional Radiology, Distinguished Reviewer Award, 2008

    Merit Award, American Society of Clinical Oncology Gastrointestinal Cancer Symposium, 2007

    Journal of Vascular and Interventional Radiology, Distinguished Reviewer Award, 2007

    Chairman, World Conference on Interventional Oncology 2nd Annual Meeting, Washington DC, 2007

    Society of Interventional Radiology Scientific Meeting Distinguished Poster Award, 2007

    Recognized as one of the Top 10 Radiologists in the USA by Medical Imaging Magazine, 2006

    Appointed to the Society of Interventional Radiology Research Foundation Board, 2006

    Appointed Founding Member of the International Liver Cancer Association, 2006

    Merit Award, American Society of Clinical Oncology Gastrointestinal Cancer Symposium, 2005

    Kodak-AUR Advanced Program Radiology Management Course, Association of University Radiologists , 2004

    Elected to AOA Honor Medical Society, 2004 Elected Fellow of the Society of Interventional Radiology (FSIR), 2004

    Certificate of Merit, American Roentgen Ray Society, 2003

    Visiting Professor, Chinese University of Hong Kong, 2002

    Ernest J. Ring Academic Development Program, SCVIR, 2001

    American Roentgen Ray Society Scholar, 2001

    Professional Activities

      

  • Videos & Media +
  • Events +
  • Contact & Locations +

    Locations

    The Johns Hopkins Hospital
    600 N. Wolfe Street
    Hospital Main Entrance - Sheikh Zayed Tower
    Baltimore, MD 21287
    Phone: 410-614-6597
    Appointment Phone: 410-614-2227
    Fax: 410-955-0233
    Location Map
    Johns Hopkins Outpatient Center
    601 N. Caroline Street
    Baltimore, MD 21287
    Phone: 410-614-2227
    Appointment Phone: 410-614-2227
    Location Map

    Department/Division

    • Radiology and Radiological Science - Vascular & Interventional Radiology

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer